Evidence map›Paper›PMID 38529272›Full record

ArticleFrontiers in immunology2024

Mannose enhances intestinal immune barrier function and dextran sulfate sodium salt-induced colitis in mice by regulating intestinal microbiota.

Yi Yang, Qiming Ma, Qingyu Wang, Lifeng Zhao, Hengshan Liu, Yanjun Chen

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. [Ecliptasaponin A ameliorates DSS-induced colitis in mice by suppressing M1 macrophage polarizationNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yi Yang *Department of Bariatric Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Qiming Ma *Department of Bariatric Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Qingyu WangDepartment of Bariatric Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Lifeng ZhaoDepartment of Pharmacy, Affiliated Cancer Hospital of Inner Mongolia Medical University, Peking University Cancer Hospital Inner Mongolia Hospital, Hohhot, China.
Hengshan LiuDepartment of Emergency and trauma, Yichang Central People's Hospital, Yichang, Hubei, China.
Yanjun ChenDepartment of Anesthesiology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
First Affiliated Hospital of Jinan University · CNPeking University Cancer Hospital · CNYichang Central People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Inflammatory bowel disease (IBD) greatly affects human quality of life. Mannose has been reported to be used to treat IBD, but the mechanism is currently unknown. Methods: C57/BL mice were used as research subjects, and the mouse acute colitis model was induced using dextran sulfate sodium salt (DSS). After oral administration of mannose, the body weights and disease activity index (DAI) scores of the mice were observed. The colon lengths, histopathological sections, fecal content microbial sequencing, colon epithelial inflammatory genes, and tight junction protein Occludin-1 expression levels were measured. We further used the feces of mice that had been orally administered mannose to perform fecal bacterial transplantation on the mice with DSS-induced colitis and detected the colitis-related indicators. Results: Oral administration of mannose increased body weights and colon lengths and reduced DAI scores in mice with DSS-induced colitis. In addition, it reduced the expression of colon inflammatory genes and the levels of serum inflammatory factors (TNF-α, IL-6, and IL-1β), further enhancing the expression level of the colonic Occludin-1 protein and alleviating the toxic response of DSS to the intestinal epithelium of the mice. In addition, gut microbial sequencing revealed that mannose increased the abundance and diversity of intestinal flora. Additionally, after using the feces of the mannose-treated mice to perform fecal bacterial transplantation on the mice with DSS-induced colitis, they showed the same phenotype as the mannose-treated mice, and both of them alleviated the intestinal toxic reaction induced by the DSS. It also reduced the expression of intestinal inflammatory genes (TNF-α, IL-6, and IL-1β) and enhanced the expression level of the colonic Occludin-1 protein. Conclusion: Mannose can treat DSS-induced colitis in mice, possibly by regulating intestinal microorganisms to enhance the intestinal immune barrier function and reduce the intestinal inflammatory response.

Indexed as

ColitisGastrointestinal MicrobiomeInflammatory Bowel DiseasesAnimalsBody WeightDextran SulfateHumansInterleukin-6MannoseMiceOccludinQuality of LifeSodium ChlorideSodium Chloride, DietaryTumor Necrosis Factor-alphaDextran SulfateInterleukin-6MannoseOccludinSodium ChlorideSodium Chloride, DietaryTumor Necrosis Factor-alphacolitisinflammationintestinal immuneintestinal microbiotamannose

Identifiers

PMID38529272
PMCPMC10961387
OpenAlexW4392658198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.